Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Expands BeiGene Tie-Up To TIGIT Inhibitor In $1bn-Plus Option Deal

Executive Summary

Latest option deal with Swiss major solidifies BeiGene’s front-runner position in PD-1 combination therapy with novel antibodies.

You may also be interested in...



Novartis’s Latecomer PD-1 Outshines Keytruda And Opdivo In Esophageal Cancer

Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.

Novartis/BeiGene Likely To Struggle In Crowded PD-1 Space Despite Positive First-Line Data

Merck’s Keytruda and BMS’s Opdivo could be tough competitors in esophageal cancer, but the Novartis/BeiGene partnership also has an anti-TIGIT drug up its sleeve.

Can Novartis Break Back Into The US Top Five? It Is Going To Need Bigger Blockbusters

Novartis has led the sector in number of launches, but has failed to find a mega-blockbuster to lift its standing in the US – its CEO hopes new leaders can help turn that around.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel